<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948753</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 04708</org_study_id>
    <nct_id>NCT00948753</nct_id>
  </id_info>
  <brief_title>Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation</brief_title>
  <official_title>Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effectiveness and safety of Maraviroc (an oral medication given
      twice daily given in addition to the standard GVHD prophylaxis) in preventing Graft versus
      Host Disease (GVHD) in patients undergoing non-myeloablative allogeneic stem-cell
      transplantation (SCT). Subjects will receive Maraviroc bid (in addition to standard GVHD
      prophylaxis) beginning after the last dose of the chemotherapy conditioning regimen until day
      30 after stem-cell infusion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy and safety of Maraviroc in prevention of acute GVHD in patients undergoing non-myeloablative allogeneic SCT.</measure>
    <time_frame>Final analysis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore pharmacokinetic profile of Maraviroc in patients undergoing nonmyeloablative allogeneic SCT</measure>
    <time_frame>Final analysis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess early mortality after transplant, rate of complications, chronic GVHD and relapse rate in patients treated with Maraviroc during SCT</measure>
    <time_frame>Final analysis</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Graft-versus-host Disease</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Phase 1: 150mg Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: 300mg Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: 300mg Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc 150 MG</intervention_name>
    <description>Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.</description>
    <arm_group_label>Phase 1: 150mg Maraviroc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc 300 mg</intervention_name>
    <description>Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.</description>
    <arm_group_label>Phase 1: 300mg Maraviroc</arm_group_label>
    <arm_group_label>Phase 2: 300mg Maraviroc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients scheduled to undergo non-myeloablative allogeneic stem-cell transplantation.

          -  meet institutional eligibility criteria for allogeneic SCT. Significant criteria are:

               -  Renal function: Serum creatinine &lt;2; or calculated creatinine clearance &gt; 40
                  mL/min/1.72m2;

               -  Hepatic function: Baseline direct bilirubin, ALT or AST lower than three times
                  the upper limit of normal;

               -  Pulmonary disease: FVC or FEV1 &gt; 40% predicted; Cardiac ejection fraction &gt; 40%.

        Exclusion Criteria:

          -  Patients not expected to be available for follow-up in our institution for at least
             100 days after the transplant

          -  Patients who are not undergoing standard non-myeloablative SCT with Flu/Bu
             conditioning and Tax/MTX GVHD prophylaxis

          -  Patients with uncontrolled bacterial, viral or fungal infections

          -  Patients who take strong inducers or inhibitors of the CYP450A4

          -  Patients receiving other investigational drugs for GVHD

          -  Women who are pregnant, plan to become pregnant or are breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Porter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2009</study_first_posted>
  <disposition_first_submitted>April 16, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 16, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 22, 2020</disposition_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Graft-versus-host disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>Maraviroc</keyword>
  <keyword>non-myeloablative allogeneic stem-cell transplantation</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

